Jeffrey Becker, MD
Urology · Bordentown, NJNPI 1699720656
Payments from drug & device makers
Across 55 payments — averaging $44.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$780
- Medtronic$313
- Neotract Inc.$215
- Teleflex LLC$172
- Stryker$166
- Boston Scientific$139
- plus $662 from 17 others
What the payments were for
- Food & beverage$2,41799%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 7 | $780 |
| Medtronic(2 entities) | 4 | $313 |
| Neotract Inc. | 5 | $215 |
| Teleflex LLC | 1 | $172 |
| Stryker | 1 | $166 |
| Boston Scientific | 3 | $139 |
| Calyxo, Inc. | 1 | $131 |
| Astellas Pharma US Inc | 8 | $127 |
| Johnson & Johnson | 5 | $70 |
| Axonics, Inc. | 3 | $57 |
| Pfizer | 2 | $43 |
| Antares Pharma, Inc. | 3 | $43 |
| Olympus America Inc. | 1 | $29 |
| Myovant Sciences Inc. | 2 | $26 |
| Dentsply IH AB | 1 | $22 |
| Rochester Medical Corporation | 1 | $19 |
| Urovant Sciences Inc | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Coloplast | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$445
- UroLift$172
- AquaBeam Robotic System$169
- 1788$166
- INTERSTIM$144
- CVAC$131
How this compares
$2,448 in reported general payments places this provider in the 50th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 150 | $137,549 |
| XyostedTestosterone Enanthate | 14 | $16,834 |
| Tamsulosin Hcl | 993 | $16,104 |
| Testosterone | 67 | $13,336 |
| GemtesaVibegron | 11 | $12,507 |
| Trospium Chloride ErTrospium Chloride | 43 | $11,140 |
| Mirabegron ErMirabegron | 19 | $8,704 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 277 | $7,723 |
| Finasteride | 417 | $6,654 |
| Oxybutynin Chloride ErOxybutynin Chloride | 235 | $5,213 |
| Potassium Citrate ErPotassium Citrate | 38 | $4,820 |
| Silodosin | 46 | $4,410 |
| Trospium Chloride | 56 | $4,094 |
| Tadalafil | 53 | $3,395 |
| Dutasteride | 84 | $3,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $127 | $137,549150 claims |
| Antares Pharma, Inc.Xyosted | $43 | $16,83414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 401 urology providers in New Jersey.
Other urology in Bordentown
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$464K
- Neil ShermanCranford$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.